The in vitro activity of difloxacin against canine bacterial isolates from clinical cases was studied in the United States and The Netherlands. Minimal inhibitory concentrations (MIC), the postantibiotic effect, the effect of pH on antimicrobial activity, and the bacterial killing rate tests were determined according to standard techniques. The MICs of American and Dutch isolates agreed in general. The MICs of the American gram-negative isolates ranged from 0.06 to 2.0 g/ml, and the MICs of the Dutch gram-negative isolates ranged from 0.016 to 8.0 g/ml. A few European strains of Proteus mirabilis and Klebsiella pneumoniae had relatively high MICs. Bordetella bronchiseptica also was less susceptible to difloxacin. The MICs of the American grampositive cocci ranged from 0.125 to 4.0 g/ml, and the MICs of Dutch isolates ranged from 0.125 to 2.0 g/ ml. Difloxacin induced a concentration-dependent postantibiotic effect that lasted 0.2-3 hours in cultures with Escherichia coli, Staphylococcus intermedius, Streptococcus canis, Proteus spp., and Klebsiella pneumoniae. There was no postantibiotic effect observed against canine Pseudomonas aeruginosa. Decreasing the pH of the medium increased the MIC of Proteus mirabilis for difloxacin. The MICs of Escherichia coli and Klebsiella pneumoniae were lowest at neutral pH and were slightly increased in acid or alkaline media. At a neutral pH, most tested bacterial species were killed at a difloxacin concentration of 4 times the MIC. Similar results were obtained when these same bacteria were tested against enrofloxacin. A Klebsiella pneumoniae strain in an acidic environment was readily killed at difloxacin or enrofloxacin MIC, but at neutral pH the drug concentration had to be raised to 4 times the MIC for a bactericidal effect. After 24 hours of incubation at pH 7.1, difloxacin and enrofloxacin had similar bactericidal activity for all bacteria tested except Staphylococcus intermedius. Against S. intermedius, difloxacin was more bactericidal than enrofloxacin.
Difloxacin HCl is a difluorinated quinolone, 1-pfluorophenyl-6-fluoro-1,4-dihydro-4-oxo-7-(4-methyl-1-piperazinyl)-3-quinolone-carboxylic acid hydrochloride, marketed for use in veterinary medicine in the United States and Europe for the treatment of canine bacterial infections in the urinary tract, the respiratory tract, and the skin. Difloxacin is an amphoteric molecule with relatively nonpolar characteristics for a quinolone. 5 Difloxacin HCl is rapidly absorbed following oral administration. Like other fluoroquinolones, difloxacin exhibits bactericidal activity primarily by binding to the A subunit of bacterial DNA-gyrase. 5 However, there is also the possibility that difloxacin might also bind to and inhibit topoisomerase. 10 Difloxacin's potency against gram-negative bacteria is similar to that of orbifloxacin and enrofloxacin, 2 other fluorinated quinolones marketed for the treatment of canine bacterial infections. Difloxacin differs from these 2 compounds by its increased activity against gram-positive bacteria. 12 Considering its in vitro activity and pharmacokinetic properties, difloxacin should be clinically effective against a wide range of gram-negative and gram-positive veterinary pathogens. The purpose of this study was to investigate the in vitro antibacterial activity of difloxacin against a variety of canine clinical bacterial isolates. The antibacterial activities investigated included determining the minimal concentration of difloxacin required to inhibit the in vitro growth of specific canine bacterial pathogens (minimal inhibitory concentration-MIC), the postantibiotic effect (PAE), the effect of pH on MICs and on bacterial killing, and the effect of increased drug concentrations on the rate of bacterial killing.
Materials and methods
Clinical bacterial isolates. The bacteria used in this study were from 2 primary sources, the United States and The Netherlands. The bacteria from the United States were isolated from clinical samples submitted to diagnostic laboratories or veterinary teaching hospitals in California, Nevada, Kansas, Kentucky, Tennessee, North Carolina, and Michigan. The Dutch isolates were obtained from the Veterinary Microbiological Diagnostic Center of the State University of Utrecht, The Netherlands. As far as could be traced, the animals from which the Dutch isolates were recovered had no history of recent antimicrobial treatment. This history was not available for the US isolates.
MIC testing. The MICs were determined in the United States in a single laboratory (Michigan State University) using a microbroth dilution technique in accordance with the procedure described in the National Committee for Clinical Laboratory Standards (NCCLS) M31-T document. 13 This procedure involved using Mueller-Hinton II (MH) broth in 96-well microtiter trays. Difloxacin dilutions ranged from 0.004 to 1.0 g/ml except for Proteus spp. Dilutions for the Proteus spp. ranged from 0.008 to 4.0 g/ml, depending on the isolate. The bacterial concentration per well was approximately 5.0 ϫ 10 4 colony-forming units (CFU). This was verified by randomly counting the number of CFU per well as described in the NCCLS M31-T document. Quality control (QC) organisms included Escherichia coli ATCC 25922 and Staphylococcus aureus ATCC 29213. Each QC organism was processed on each test tray. The microtiter trays were incubated at 37 C for 18-24 hr. The MIC was recorded as the lowest concentration of difloxacin that completely inhibited the growth of the bacterial isolates as determined visually.
The MICs in The Netherlands were determined by the agar plate dilution technique a with difloxacin dilutions of 0.008-8 g/ml, according to standard procedures. 16 Twentyfive milliliters of medium, pH 7.4, was dispensed into 99mm plates, resulting in an agar depth of 4 mm. The medium was supplemented with defibrinated sheep blood for Streptococcus, Pasteurella, and Bordetella spp. Using a multipoint inoculator, 10 3 CFU/isolate was inoculated on each plate. Eighteen clinical isolates and 2 QC strains were tested on each plate. Each isolate was tested in duplicate. The inoculated plates were incubated for 18-24 hr at 37 C under atmospheric conditions.
Determination of the in vitro PAE of difloxacin. The PAE of difloxacin was tested against 60 canine clinical bacterial isolates. These isolates included 10 each of Staphylococcus intermedius, Streptococcus canis, E. coli, Proteus spp., Pseudomonas aeruginosa, and Klebsiella pneumoniae. These tests were performed in accordance with procedures described previously. 3 A 1.0-ml aliquot of a 10 7 CFU/ml bacterial suspension was diluted 1:10 in 9.0 ml of MH broth containing difloxacin concentrations of no drug (control) and 1, 2, 4, and 8 times the MIC of each bacterium being tested. After a 1-hr incubation at 37 C in an oscillating water bath, all 5 suspensions were subjected to 3 wash cycles by pelleting the bacteria by centrifugation at 2,000 ϫ g for 10 min, resuspending the pelleted bacteria in its original volume of prewarmed MH broth, and repeating the cycle 2 more times. Following the last wash, the bacteria were resuspended to their original volume in prewarmed MH broth incubated at 37 C in the oscillating water bath. Bacterial counts were performed on the control suspensions and on each drugbacteria suspension immediately after the addition of bacteria to the drug suspensions, on the resuspended bacteria after the third wash, and at hourly intervals for up to 8 hr postwashing or until the growth in the suspensions had increased to approximately 10 8 CFU/ml as determined by a colorimeter. Bacterial counts were accomplished by removing a 0.2-ml aliquot from each suspension at the appropriate time and performing serial 10-fold dilutions in sterile water. Appropriate dilutions were plated on MH agar plates, except Proteus spp., which were plated on MacConkey agar. The number of CFU/ml at each sampling time was then graphed, and the PAE was determined using a combination of graphic evaluation and the equation PAE ϭ T Ϫ C, where T is the time required for the number of colonies in the test culture to increase 1 log 10 CFU/ml above the count obtained immediately after the third wash and C is the time required for the number of colonies in the untreated controls to increase by 1 log 10 CFU/ml above the count obtained immediately after the third wash.
Effect of pH on antimicrobial activity. Thirty-three isolates from dogs with recurrent urinary tract infections were tested. The pH of the agar plates used for MIC testing was adjusted with NaOH or HCl to 5.9, 7.1, and 7.9. Inoculation, incubation, and interpretation of the growth results were as described above.
Bacterial killing rate tests. Eight clinical isolates from dogs with recurrent urinary tract infections and 2 control strains, E. coli ATCC 25922 and Staphylococcus aureus ATCC 25923, were used to measure the extent and the speed of killing of canine clinical isolates. The clinical isolates included 2 E. coli strains, 1 K. pneumoniae strain, 3 Proteus mirabilis strains, and 2 S. intermedius strains. Bacterial suspensions from overnight broth cultures were diluted to approximately 10 9 CFU/ml by using 0.01 ml inoculate into glass tubes with 10 ml medium. a For fastidious organisms, 5% defibrinated sheep blood was added. Control medium and media containing a difloxacin concentration of 0.25, 1, and 4 times the MIC of the tested organisms were prepared. As a control, enrofloxacin was used in the same concentration range. The time-kill relationship was studied at 3 different pHs, 6.1, 7.1 and 8.1. At 0, 1, 2, and 24 hr after incubation at 37 C, 1.0-ml samples were drawn from the test tubes for bacterial counts. Each 1.0-ml sample was subjected to serial 10-fold dilutions. From these dilutions, the CFU was determined, and the killing rate constant was calculated from these results. A decrease of 3 log 10 CFU was considered a bactericidal effect. This value corresponded with the killing of 99.9% of the bacteria present in the medium.
Results
The in vitro susceptibilities of the American isolates and the Dutch isolates to difloxacin are shown in Tables 1 and 2, respectively. For bacteria tested in the United States, the gram-negative bacteria appeared to be more susceptible than the gram-positive bacteria to difloxacin, except for Proteus spp. This also was true for the isolates tested in The Netherlands, except for P. mirabilis, K. pneumoniae, and Bordetella bronchiseptica, which had higher MICs than did the grampositive isolates. The PAEs exhibited by difloxacin appeared to be bacterium and concentration dependent. Difloxacin induced a PAE against canine strains of E. coli, S. intermedius, Proteus spp., Streptococcus canis, and K. pneumoniae but not against canine isolates of Pseudomonas aeruginosa. The PAE increased by increasing the concentrations of difloxacin for Staphylococcus intermedius, E. coli, and Proteus spp. but not Table 4 . The MIC for P. mirabilis was affected the most by changes in the pH. For all organisms tested, difloxacin was most active at a physiologic pH.
The mean change in the CFU/ml over time of 3 E. coli strains and 3 Staphylococcus strains is shown in Figs. 1-4 . Although the concentration-dependent killing was similar for difloxacin and enrofloxacin when tested against E. coli, difloxacin had a much greater concentration killing effect against S. intermedius than did enrofloxacin (Figs. 3, 4) .
The speed at which this bacterial killing took place is expressed as rate constant ( Table 5 ). The bacteria were exposed to difloxacin or enrofloxacin for 2 and 4 hours. A rate constant of 0.29 represented a 99.9% kill rate if the bacteria had been exposed to the drugs for 24 hours. Both difloxacin and enrofloxacin exhibited excellent bactericidal activity against all 3 gram-negative bacteria tested. Against S. intermedius, difloxacin was more active than enrofloxacin. When tested at the MIC, the killing rate for most isolates was minimal ( Figs. 1-4 ).
Discussion
The antibacterial effect of difloxacin was evaluated against canine pathogens that were considered to be the most common bacterial species isolated from urinary tract infections, soft tissue and skin infections, and the lower respiratory tract. 1, 2, 7, 9, 11 For the United States isolates, the MICs were similar to those seen for canine bacterial isolates from the same time period, tested against enrofloxacin. 17 Escherichia coli, Klebsiella spp., Enterobacter spp., Pseudomonas spp., and Pasteurella spp. were more susceptible than were Staphylococcus, Streptococcus, and Proteus. The increased MICs for difloxacin when tested against Proteus spp. are consistent with the MICs of enrofloxacin for Proteus. 17 The susceptibilities of the Staphylococcus and Streptococcus isolates from the United States were the same as those for the Dutch isolates, as was the case for the gram-negative bacteria, even though 2 different testing methods were used. This observation was confirmed by the use of the same QC organisms, which were tested in accordance with the NCCLS standards. Although there were no QC ranges for difloxacin at the time the tests were performed, there were QC ranges for enrofloxacin, and the MICs generated in both laboratories were in agreement.
The MICs of the canine isolates tested in this study were similar to those reported for human isolates 15 and for canine and feline isolates. 14 The MIC 90 of difloxacin was 0.25 g/ml against E. coli, 0.5 g/ml against K. pneumoniae, 2.0 g/ml against P. mirabilis, 0.25 Staphylococcus aureus and 1.0 g/ml against Staphylococcus epidermis. 15 Similar results were obtained when canine and feline isolates were tested against marbofloxacin. 14 When tested against gram-positive isolates, difloxacin exhibited a PAE that was drug concentration dependent. The PAE of Staphylococcus intermedius increased with increasing concentrations of difloxacin, whereas for Streptococcus canis there appeared to be an optimum concentration of 2 times the MIC, with higher concentrations appearing to decrease the PAE. For E. coli, the PAE increased with increasing concentrations, but not as strongly as with Staphylococcus intermedius. Klebsiella pneumoniae had a relative low PAE, with an optimum at twice the MIC. Difloxacin did not induce a PAE when tested against Pseudomonas aeruginosa at the concentrations tested. The PAE of difloxacin was rather similar to that described for marbofloxacin and enrofloxacin. 14 The effect of pH on the activity of difloxacin on canine and human isolates also appears similar. In general there was no difference in activity at acid and neutral pH, but at alkaline pH the effective drug concentration was only attained at the 4-fold level. Others have described similar results for the killing of gram- negative and gram-positive organisms of human origin by difloxacin. 4 In the present study, difloxacin concentrations of 1-4 times the MIC had a bactericidal effect on gram-negative bacteria after 6 hours of incubation, whereas gram-positive cocci were only inhibited for 6 hours. However, after 24 hours of exposure, difloxacin was also bactericidal to these gram-positive cocci. Enrofloxacin, on average, was never bactericidal in the time-kill studies. Similar results of killing kinetics as seen with difloxacin were reported for marbofloxacin. 14 The relationship between bactericidal and inhibitory properties of an antimicrobial drug on isolates can be expressed as a minimal bactericidal concentration (MBC)/MIC ratio. The small MBC/MIC ratio that was seen with difloxacin for canine isolates was also previously reported for human isolates. 8 In a study in which the geometric mean MIC and MBC of 10 isolates were calculated, 14 the MIC was the MBC for E. coli, K. pneumoniae, and Proteus mirabilis, and the MBC was on average 2 times higher than the MIC for Pseudomonas aeruginosa and S. aureus. Marbofloxacin and enrofloxacin in general needed concentrations of 4 times the MIC to obtain sufficient killing of most bacteria. 14 Difloxacin, a new fluoroquinolone recently introduced to the veterinary market, generally has good broad-spectrum antibacterial effect. Compared with enrofloxacin and marbofloxacin, difloxacin appears to have slightly higher MICs but exhibits a more pronounced bactericidal effect; the MBC/MIC ratio was narrower and the rate at which it kills most bacteria in general is higher. These results are supported by in vivo activity studies such as a mouse systemic infection model, a mouse pyelonephritis model, and a mouse pneumonia model. 6 Mice orally dosed with di-floxacin in these models often were effectively protected against lethal infection with E. coli, Salmonella typhimurium, P. aeruginosa, Staphylococcus aureus, Streptococcus pyogenes, and S. pneumoniae. Difloxacin was often comparatively more effective than aminoglycosides or beta-lactams.
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a. Iso-Sensitest agar, Oxoid, Haarlem, The Netherlands.
